Cargando…
Bevacizumab for Glioblastoma—A Promising Drug or Not?
Two double blind, placebo-controlled, and randomized phase III studies were conducted, and the results including OS’s were reported at the ASCO Meeting in June 2013, which was the beginning of confusion surrounding this topic. This is a review article not only summarizing the previous evidence, but...
Autores principales: | Nagane, Motoo, Nishikawa, Ryo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875948/ https://www.ncbi.nlm.nih.gov/pubmed/24213559 http://dx.doi.org/10.3390/cancers5041456 |
Ejemplares similares
-
Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study
por: Motoo, Nagane, et al.
Publicado: (2019) -
Dose-dense Temozolomide: Is It Still Promising?
por: NAGANE, Motoo
Publicado: (2015) -
SS-1 Therapeutic challenges for glioblastoma: Temozolomide and its issues?
por: Nagane, Motoo
Publicado: (2020) -
Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma(†)
por: Nagane, Motoo, et al.
Publicado: (2012) -
Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)